What: The FDA has officially agreed that the drug shortage around GLP-1 weight loss drugs has ended, meaning the tens of thousands of Americans taking lower cost “compound” versions of the drugs (often because insurance won’t cover the brand names) will have to find another source in the coming weeks.
Key line: “The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until March 19 to stop, according to the FDA. For Wegovy, larger, national licensed facilities have until May 22, to stop making compound versions, according to the FDA.”
Source: ABC News